Cannabinoid treatment for autism: a proof-of-concept randomized trial.

Adi AranMoria HarelHanoch CassutoLola PolyanskyAviad SchnappNadia WattadDorit ShmueliDaphna GolanF Xavier Castellanos

Published in: Molecular autism (2021)

This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended. Trial registration ClinicalTrials.gov: NCT02956226. Registered 06 November 2016, https://clinicaltrials.gov/ct2/show/NCT02956226.

Keyphrases

autism spectrum disorder
intellectual disability
computed tomography
attention deficit hyperactivity disorder
physical activity
phase iii
magnetic resonance imaging
phase ii
contrast enhanced
dual energy
magnetic resonance
positron emission tomography
open label
smoking cessation
cone beam